A Bayesian adaptive phase 1 design to determine the optimal dose and schedule of an adoptive T-cell therapy in a mixed patient population.

@article{Quintana2016ABA,
  title={A Bayesian adaptive phase 1 design to determine the optimal dose and schedule of an adoptive T-cell therapy in a mixed patient population.},
  author={Melanie Quintana and Daniel Teng Hui Li and Tina M. Albertson and Jason Connor},
  journal={Contemporary clinical trials},
  year={2016},
  volume={48},
  pages={153-65}
}
We present a novel Bayesian adaptive phase 1 design to determine the optimal dosing regimen for an adoptive T-cell therapy in a mixed patient population. Our design is motivated by a B-cell Non-Hodgkin Lymphoma trial evaluating multiple dosing regimens within multiple disease subtypes. A utility score is calculated from both safety and efficacy utility… CONTINUE READING